Specify a stock or a cryptocurrency in the search bar to get a summary
Galmed Pharmaceuticals Ltd
GLMDGalmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Address: 16 Tiomkin Street, Tel Aviv, Israel, 6578317
Analytics
WallStreet Target Price
1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GLMD
Dividend Analytics GLMD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GLMD
Stock Valuation GLMD
Financials GLMD
Results | 2019 | Dynamics |